(ILMN) Illumina - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 17.992m USD | Total Return: 61.5% in 12m

Stock Genetic Analysis, Sequencing, Instruments, Reagents, Kits
Total Rating 74
Risk 87
Buy Signal -0.02
Diagnostics & Research +11.6
Life Sciences Tools & Services +17.4
Market Cap: 17,992m
Avg Trading Vol: 174M USD
ATR: 4.19%
Peers RS (IBD): 91.1
Risk 5d forecast
Volatility44.1%
Rel. Tail Risk-6.17%
Reward TTM
Sharpe Ratio1.05
Alpha36.20
Character TTM
Beta0.964
Beta Downside0.940
Drawdowns 3y
Max DD68.94%
CAGR/Max DD-0.26
EPS (Earnings per Share) EPS (Earnings per Share) of ILMN over the last years for every Quarter: "2021-03": 1.89, "2021-06": 1.87, "2021-09": 1.45, "2021-12": 0.75, "2022-03": 1.07, "2022-06": 0.57, "2022-09": 0.34, "2022-12": 0.14, "2023-03": 0.08, "2023-06": 0.32, "2023-09": 0.33, "2023-12": 0.14, "2024-03": 0.09, "2024-06": 0.36, "2024-09": 1.14, "2024-12": 0.86, "2025-03": 0.97, "2025-06": 1.19, "2025-09": 1.34, "2025-12": 1.35, "2026-03": 0,
EPS CAGR: -53.23%
EPS Trend: 52.1%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ILMN over the last years for every Quarter: 2021-03: 1093, 2021-06: 1126, 2021-09: 1108, 2021-12: 1199, 2022-03: 1223, 2022-06: 1162, 2022-09: 1115, 2022-12: 1084, 2023-03: 1087, 2023-06: 1176, 2023-09: 1119, 2023-12: 1122, 2024-03: 1076, 2024-06: 1112, 2024-09: 1080, 2024-12: 1104, 2025-03: 1041, 2025-06: 1059, 2025-09: 1083, 2025-12: 1159, 2026-03: null,
Rev. CAGR: -1.42%
Rev. Trend: -50.4%
Last SUE: 3.20
Qual. Beats: 2
Risks
Technicals: choppy
Description: ILMN Illumina

Illumina, Inc. (ILMN) provides genetic and genomic analysis solutions. These solutions include sequencing and array-based instruments and consumables, such as reagents and whole-genome sequencing kits.

The company also offers various services, including whole-genome sequencing and noninvasive prenatal testing. Genomics is a rapidly advancing field with applications across healthcare and research.

Illumina serves a diverse customer base, including research centers, hospitals, and pharmaceutical companies. Its business model relies on both direct sales and distribution through life-science distributors. The life sciences tools and services sector is characterized by continuous innovation and high capital expenditure.

To gain a deeper understanding of Illuminas market position and financial health, further research on platforms like ValueRay is recommended.

Headlines to Watch Out For
  • Sequencing instrument sales drive capital expenditure
  • Consumable recurring revenue fuels growth
  • Research and clinical demand dictates sales volume
  • Regulatory approvals impact diagnostic market access
  • Competition in sequencing technology affects market share
Piotroski VR‑10 (Strict) 8.0
Net Income: 850.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.88 > 1.0
NWC/Revenue: 39.24% < 20% (prev 27.42%; Δ 11.82% < -1%)
CFO/TA 0.16 > 3% & CFO 1.08b > Net Income 850.0m
Net Debt (1.14b) to EBITDA (1.46b): 0.78 < 3
Current Ratio: 2.08 > 1.5 & < 3
Outstanding Shares: last quarter (154.0m) vs 12m ago -3.75% < -2%
Gross Margin: 66.49% > 18% (prev 0.65%; Δ 6.58k% > 0.5%)
Asset Turnover: 67.07% > 50% (prev 69.36%; Δ -2.29% > 0%)
Interest Coverage Ratio: 9.41 > 6 (EBITDA TTM 1.46b / Interest Expense TTM 126.0m)
Altman Z'' 2.61
A: 0.26 (Total Current Assets 3.29b - Total Current Liabilities 1.58b) / Total Assets 6.64b
B: -0.06 (Retained Earnings -392.0m / Total Assets 6.64b)
C: 0.18 (EBIT TTM 1.19b / Avg Total Assets 6.47b)
D: -0.10 (Book Value of Equity -400.0m / Total Liabilities 3.92b)
Altman-Z'' Score: 2.61 = A
Beneish M -3.02
DSRI: 1.15 (Receivables 854.0m/751.0m, Revenue 4.34b/4.37b)
GMI: 0.98 (GM 66.49% / 65.44%)
AQI: 0.91 (AQ_t 0.34 / AQ_t-1 0.37)
SGI: 0.99 (Revenue 4.34b / 4.37b)
TATA: -0.03 (NI 850.0m - CFO 1.08b) / TA 6.64b)
Beneish M-Score: -3.02 (Cap -4..+1) = AA
What is the price of ILMN shares? As of April 02, 2026, the stock is trading at USD 123.26 with a total of 1,383,138 shares traded.
Over the past week, the price has changed by +0.34%, over one month by -4.71%, over three months by -5.75% and over the past year by +61.54%.
Is ILMN a buy, sell or hold? Illumina has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold ILMN.
  • StrongBuy: 7
  • Buy: 5
  • Hold: 11
  • Sell: 2
  • StrongSell: 0
What are the forecasts/targets for the ILMN price?
Wallstreet Target Price 136.1 10.4%
Analysts Target Price 136.1 10.4%
ILMN Fundamental Data Overview as of 31 March 2026
P/E Trailing = 21.5908
P/E Forward = 22.9358
P/S = 4.1427
P/B = 6.6073
P/EG = 2.1437
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 577.0m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.13b USD (17.99b + Debt 2.55b - CCE 1.42b)
Interest Coverage Ratio = 9.41 (Ebit TTM 1.19b / Interest Expense TTM 126.0m)
EV/FCF = 20.37x (Enterprise Value 19.13b / FCF TTM 939.0m)
FCF Yield = 4.91% (FCF TTM 939.0m / Enterprise Value 19.13b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.88 (Enterprise Value 19.13b / Total Assets 6.64b)
Interest Expense / Debt = 1.02% (Interest Expense 26.0m / Debt 2.55b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.94 (Debt 2.55b / totalStockholderEquity, last quarter 2.72b)
Debt / EBITDA = 0.78 (Net Debt 1.14b / EBITDA 1.46b)
Debt / FCF = 1.21 (Net Debt 1.14b / FCF TTM 939.0m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 34.94% (Net Income TTM 850.0m / Total Stockholder Equity 2.43b)
RoCE = 30.24% (EBIT 1.19b / Capital Employed (Equity 2.43b + L.T.Debt 1.49b))
RoIC = 23.69% (NOPAT 1.05b / Invested Capital 4.42b)
WACC = 8.32% (E(17.99b)/V(20.54b) * Re(9.37%) + D(2.55b)/V(20.54b) * Rd(1.02%) * (1-Tc(0.12)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF] Terminal Value 80.56% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
[DCF] Fair Price = 180.6 (EV 28.75b - Net Debt 1.14b = Equity 27.61b / Shares 152.9m; r=8.32% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 52.11 | EPS CAGR: -53.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.25 | Chg7d=+0.004 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=16
EPS current Year (2026-12-31): EPS=5.13 | Chg7d=+0.007 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+5.9% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=5.84 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+13.9% | Growth Revenue=+5.7%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 9.4% - Earnings Yield 4.6%)
[Growth] Growth Spread = -0.5% (Analyst 4.2% - Implied 4.7%)
External Resources
Dataroma Stockcircle